Factors influencing serum chemerin and kallistatin concentrations in patients with alcohol-induced liver cirrhosis
More details
Hide details
Department of Internal Medicine, Medical University, Lublin, Poland
Department of Experimental Haematooncology, Medical University, Lublin, Poland
Department of Medical Chemistry, Medical University, Lublin, Poland
Department of Ethics and Human Philosophy, Medical University, Lublin, Poland
Independent Public Teaching Hospital No. 4, Lublin, Poland
Students’ Scientic Society, Medical University, Lublin, Poland
Department of Internal Diseases and Hypertension, Institute of Rural Health, Lublin, Poland
Department of Nephrology, Medical University, Lublin, Poland
In Poland, an increasing number of patients are hospitalized due to liver diseases. One of the common liver diseases is cirrhosis, which can be caused by alcohol, viral hepatitis, autoimmune processes and metabolic diseases.

Material and methods:
The study included 99 patients with alcoholic cirrhosis from the Lublin region of Eastern Poland. The control group consisted of 20 healthy individuals without liver disease who did not abuse alcohol. The concentrations of serum kallistatin and chemerin were determined using ELISA kits.

The aim of the study is to evaluate serum levels of kallistatin and chemerin in patients with different stages of alcoholic liver cirrhosis.

The highest chemerin level was found in the control group – 182.6±80.4 ng/ml. In other stages of liver cirrhosis, the following levels were observed: 175.7±62.7 ng/ml in Child-Pugh stage A (Ch-P A), 150.2±59.7 ng/ml in Ch-P B and 110.3±73.6 ng/ml in Ch-P C. Significant differences in chemerin levels between controls and Ch-P C patients (p=0.01), as well as between the Ch-P A patients and Ch-P C patients (p=0.02), were demonstrated. The highest kallistatin level was demonstrated in the control group – 8.2±3.5 μg/ml. In other stages of liver cirrhosis, the following concentrations were found: 7.2±27 μg/ml in Ch-P A, 4.4±2.2 μg/ml in Ch-P B and 3.5±1.9 μg/ml in Ch-P C. Statistically significant differences were observed between controls and Ch-P B patients (p<0.001), controls and Ch-P C patients (p<0.001), Ch-P A and Ch-P B patients (p=0.01), as well as Ch-P A and Ch-P C patients (<0.001).

The levels of chemerin and kallistatin decrease with progression of liver damage during alcoholic liver cirrhosis. The impairment of its synthetic function leads to reductions in levels of the adipokines studied.

Andrzej Prystupa   
Department of Internal Medicine, Medical University, Lublin, Poland
1. Bosetti C, Levi F, Lucchini F, Zatonski WA, Negri E, La Vecchia C. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol. 2007; 46: 827–839.
2. Bruha R, Dvorak K, Petrtyl J. Alcoholic liver disease. World J Hepatol. 2012; 4(3): 81–90.
3. Ishii H, Horie Y, Yamagshi Y, Ebinuma H. Alcoholic Liver Disease and Its Relationship with Metabolic Syndrome. JMAJ. 2010; 53(4): 236–242.
4. Krautbauer S, Wanninger J, Eisinger K, Hader Y, Beck M, Kopp A, Schmid A, Weiss TS, Dorn C, Buechler C. Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver. Exp Mol Pathol. 2013; 95(2): 199–205.
5. Strojek M. Chemeryna – rola w patologii człowieka. Postepy Hig Med Dosw (online), 2017; 71: 110-117.
6. Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, Lebherz C, Tittus J, Reiser M, Becker C, Göke B, Leber AW, Parhofer KG, Broedl UC. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009; 161: 339-344.
7. Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, Farkas S, Scherer MN, Schäffler A, Aslanidis C, Schölmerich J, Buechler C. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol. 2010; 72: 342-348.
8. Cheng Z, Lv Y, Pang S, Bai R, Wang M, Lin S, Xu T, Spalding D, Habib N, Xu R. Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. Acta Pharm Sin B. 2015; 5(3): 194–200.
9. Shen B, Hagiwara M, Yao YY, Chao L, Chao JL. Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension. 2008; 51: 1358–1365.
10. Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood. 2002; 100: 3245–3325.
11. Pugh R, Murray-Lyon I, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973, 60(8): 646–649.
12. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007; 282(38): 28175–28188.
13. Zabel BA, Allen SJ, Kulig P, Allen JA, Cichy J, Handel TM, Butcher EC. Chemerin Activation by Serine Proteases of the Coagulation, Fibrinolytic, and Inflammatory Cascades. J Biol Chem. 2005; 280: 34661–34666.
14. Eisinger K, Krautbauer S, Wiest R, Weiss TS, Buechler C. Reduced serum chemerin in patients with more severe liver cirrhosis. Exp Mol Pathol. 2015; 98(2): 208–213.
15. Błaszak J, Szołkiewicz M, Sucajtys E, Konarzewski M, Świerczyński J, Rutkowski B. High serum chemerin concentration in patient with chronic renal failure. Nephrol Dial Pol. 2013, 17, 49–52.
16. Kukla, M, Zwirska-Korczala K, Gabriel A, Waluga M, Warakomska I, Szczygiel B, Berdowska A, Mazur W, Wozniak-Grygiel E, Kryczka W. Chemerin, vaspin and insulin resistance in chronic hepatitis C. J Viral Hepat. 2010; 17(9): 661–667.
17. Kukla M, Zwirska-Korczala K, Hartleb M, Waluga M, Chwist A, Kajor M, Ciupinska-Kajor M, Berdowska A, Wozniak-Grygiel E, Buldak R. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2010; 45(2): 235–42.
18. Imai K, Takai K, Hanai T, Shiraki M, Suzuki Y, Hayashi H, Naiki T, Nishigaki Y, Tomita E, Shimizu M, Moriwaki H. Impact of serum chemerin levels on liver functional reserves and platelet counts in patients with hepatocellular carcinoma. Int J Mol Sci. 2014; 15(7): 11294–11306.
19. Chao J, Schmaier A, Chen LM, Yang Z, Chao L. Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med. 1996; 127: 612–620.
20. Chao J, Chao L. Biochemistry, regulation and potential function of kallistatin. Biol Chem Hoppe-Seyler. 1995; 376: 705–713.
21. Cheng Z, Lv Y, Pang S, Bai R, Wang M, Lin S, Xu T, Spalding D, Habib N, Xu R. Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. Acta Pharm Sin B. 2015; 5 (3): 194–200.
22. Chao J, Chen LM, Chai KX, Chao L. Expression of kallikrein-bonding protein and α1-antitrypsin genes in response to sex hormones, growth, inflammation and hypertension. Agents Actions Suppl. 1992; 38: 174–181.